Biorce, a Barcelona-based HealthTech company transforming clinical trials through artificial intelligence, has today announced the closing of a €43.8 million ($52 million) Series A round to support international expansion, hire and accelerate product development.
The round features new funding from DST Global Partners, with existing investors Norrsken VC and YZR Capital expanding their involvement, along with Mustard Seed Maze. It also includes notable angel investors like Arthur Mensch, co-founder and CEO of Mistral AI; Albert Nieto, founder of Seedtag; Paulo Rosado, founder of OutSystems; and Nik Storonsky, CEO of Revolut.
According to Biorce, this round is the largest Series A ever in the Iberian HealthTech and AI ecosystem to date. Over a 12 month period, the company closed €8.5 million in Seed funding, comprising a €3.5 million round in November 2024 and a subsequent €5 million extension from Norrsken VC in summer 2025, and now the €43.8 million Series A round. With this round, the company has raised a total of over €50.6 million ($60 million) in funding.
Pedro Coelho, CEO of Biorce, commented, “This $52 million (€43.8 million) round reflects both the scale of the problem we are addressing and the market’s confidence in our vision. Clinical trial delays and inefficiencies cost time, money, and ultimately lives. Our mission is to make trials faster, more reliable, and more accessible, so patients can benefit from new treatments sooner. The speed at which we have raised capital since our last round in July 2025 is a strong validation of our technology, our team, and the impact we can generate.”
Biorce was founded in 2024 with the mission to fix the clinical trial industry. It aims to slash the cost of clinical trials by over 50% and help life-saving treatments reach patients sooner.
According to the company, clinical trials take nearly 11 years and cost €5.2 billion ($6.2 billion) to bring a drug to market, with 57% facing costly protocol amendments that add months of delay. Citing SNS Insider, Biorce notes that clinical trials management represents an estimated €101.2 billion ($120 billion) in global annual spend.
With the traditional model, each protocol amendment typically halts patient recruitment for an average of six weeks and adds between €500k and €1 million in costs, resulting in billions of euros in annual expenditure across the industry.
The Spanish startup claims that a core challenge is that many teams struggle to clearly justify their design decisions to regulatory agencies such as the FDA and the EMA. This often leads to reviews, delays, and additional amendments, ultimately slowing patient access to treatments.
As a solution, Biorce has developed Aika, a native AI platform that reduces clinical trial preparation timelines and protocol amendments, accelerating the development of new therapies by up to 50%.
The platform has been built upon a proprietary data foundation of around 1 million clinical trials and enables pharmaceutical companies, biotech firms, and CROs to design better trials faster, without compromising scientific rigour or patient safety.
It claims that its AI platform streamlines protocol development, site selection, and feasibility assessment, with the aim of reducing complexity, accelerating timelines, and improving operational efficiency.
Discussing how Aika differs from other AI platforms in pharma, the company mentioned, “Most AI solutions ask you to trust algorithms you can’t explain. We built the opposite. Every Aika recommendation comes with complete documentation that you can defend before any regulatory authority. Our “human-in-the-loop” approach ensures the expert stays in control.”
According to the company, Aika is already in use across multiple therapeutic areas, including oncology, neurology, and rare diseases. Aika’s therapy-agnostic approach allows Biorce to scale the impact of AI across a range of clinical programmes.
The fresh capital will enable Biorce to support international expansion, particularly into the United States. The company is preparing the launch of a development and R&D hub in Austin, Texas.
The funding will also support plans to expand the team to around 250 employees by the end of 2026, with a focus on scaling the engineering and commercial teams. It is also speeding up product development. Biorce also reported that it ended last year at approximately 200% above its revenue target.
“The platform is already seeing strong global demand, proving it can materially reduce timelines and costs for pharma and, more importantly, bring new treatments to patients faster than previously possible. That’s why we’re excited to double down on our investment. Their expansion into the U.S. is a natural next step and further cements the company’s trajectory toward becoming a category-defining force in clinical research,” said Tove Larsson, General Partner at Norrsken VC, Board Member.
In the first quarter of 2026, the team will focus on bolstering Aika’s protocol intelligence capabilities and introducing new modules such as contract management and negotiation tools. Additional features will also be included to support budget negotiation and operational planning. To support its next phase of growth, Biorce is finalising a move to larger offices in Barcelona.
Read the orginal article: https://www.eu-startups.com/2026/02/barcelona-biorce-closes-e43-8-million-series-a-to-accelerate-ai-driven-clinical-trials/
